Peptic ulcer disease (PUD) is a prevalent gastrointestinal disorder characterized by the erosion of the gastric or duodenal mucosa. Despite the advances in understanding its etiology and treatment, managing PUD remains a clinical challenge due to its multifactorial nature and the increasing prevalence of drug-resistant strains of Helicobacter pylori.
The pathogenesis of PUD involves an imbalance between aggressive factors such as gastric acid, pepsin, and H. pylori, and defensive factors like bicarbonate, prostaglandins, and mucus. H. pylori infection plays a pivotal role, with its virulence factors disrupting the mucosal defense and promoting inflammation.
Diagnosis of PUD includes a combination of clinical history, physical examination, and confirmatory tests. Endoscopy is the gold standard for diagnosis, providing direct visualization of the ulcer and facilitating biopsy for H. pylori detection. Non-invasive tests such as urea breath test and stool antigen test are also useful.
Management of PUD primarily focuses on eradicating H. pylori and reducing gastric acidity. The standard regimen includes a proton pump inhibitor and two antibiotics for 10-14 days. However, the rising rates of antibiotic resistance necessitate the use of quadruple therapy or tailored regimens based on local resistance patterns.
Alongside pharmacological treatment, lifestyle modifications play a crucial role in PUD management. These include smoking cessation, limiting alcohol and NSAID use, and dietary changes. Although no specific diet can prevent or cure PUD, a balanced diet can help maintain overall health and enhance drug efficacy.
Peptic ulcer disease management requires a comprehensive approach that encompasses an understanding of the complex pathophysiology, appropriate diagnostic strategies, effective therapeutic regimens, and lifestyle modifications. Continued research and education are essential to optimize patient outcomes and tackle the challenges posed by antibiotic resistance.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation